Clinical application of blood biomarkers in cerebrovascular disease

Expert Review of Neurotherapeutics

Volumn 10, Issue 2, 2010, Pages 189-203

  El Husseini, Nada ^a   Laskowitz, Daniel T ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Diagnosis; Inflammation; Oxidative stress; Prognosis; Risk stratification; Stroke

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM; CELL ADHESION MOLECULE; D DIMER; DJ 1 PROTEIN; FATTY ACID BINDING PROTEIN; FIBRINOGEN; FIBRONECTIN; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; HEMOGLOBIN; INTERLEUKIN 6; MALONALDEHYDE; MYELIN BASIC PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N(G),N(G) DIMETHYLARGININE; NEURON SPECIFIC ENOLASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN; PROTEIN S100B; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISIN LIKE PROTEIN 1; VON WILLEBRAND FACTOR;

BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN VASOSPASM; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; INFLAMMATION; LIPID PEROXIDATION; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OXIDATION; OXIDATIVE STRESS; PREDICTION; PROGNOSIS; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK;

BIOLOGICAL MARKERS; HUMANS; STROKE;

EID: 76249108245     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.151     Document Type: Review

References (114)

1. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 113(10), e409-e449 (2006).
2. Jensen MB, Chacon MR, Sattin JA, Aleu A, Lyden PD. The promise and potential pitfalls of serum biomarkers for ischemic stroke and transient ischemic attack. Neurologist 14(4), 243-246 (2008).
3. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 40(1), 77-85 (2009). • First large multicenter trial assessing a panel of biomarkers for the diagnosis of stroke using stroke mimics as the control group and validating the panel in a separate cohort.
4. Chalela JA, Kidwell CS, Nentwich LM et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 369(9558), 293-298 (2007).
5. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56(8), 1015-1020 (2001).
6. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2(7), 566-580 (2003). • Clearly defines a biomarker and its potential applications in drug discovery.
7. Howes JM, Keen JN, Findlay JB, Carter AM. The application of proteomics technology to thrombosis research: the identification of potential therapeutic targets in cardiovascular disease. Diab. Vasc. Dis. Res. 5(3), 205-212 (2008).
8. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH. Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology 73(5), 393-399 (2009).
9. Manolio T. Novel risk markers and clinical practice. N. Engl. J. Med. 349(17), 1587-1589 (2003).
10. Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke 39(10), 2902-2909 (2008). •• Excellent systematic review of diagnostic biomarkers in ischemic stroke describing current limitations and providing recommendations for the design of future studies.
11. Laterza OF, Modur VR, Crimmins DL et al. Identification of novel brain biomarkers. Clin. Chem. 52(9), 1713-1721 (2006).
12. Reynolds MA, Kirchick HJ, Dahlen JR et al. Early biomarkers of stroke. Clin. Chem. 49(10), 1733-1739 (2003).
13. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 37(10), 2508-2513 (2006). • Good prospective study of prognostic stroke biomarkers in a large number of patients that were enrolled in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
14. Wijdicks EF, Hijdra A, Young GB, Bassetti CL, Wiebe S. Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 67(2), 203-210 (2006).
15. Herrmann M, Ehrenreich H. Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor. Neurol. Neurosci. 21(3-4), 177-190 (2003).
16. Fassbender K, Schmidt R, Schreiner A et al. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J. Neurol. Sci. 148(1), 101-105 (1997).
17. Anand N, Stead LG. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc. Dis. 20(4), 213-219 (2005).
18. Akpinar O, Geyik S, Acikalin A, Karakan Y, Tiryaki O. H-FABP in the early diagnosis of stroke. J. Neurol. 256(11), 1922-1923 (2009).
19. Lescuyer P, Allard L, Hochstrasser DF, Sanchez JC. Heart-fatty acid-binding protein as a marker for early detection of acute myocardial infarction and stroke. Mol. Diagn. 9(1), 1-7 (2005).
20. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol. Cell. Proteomics 3(1), 66-72 (2004).
21. Wunderlich MT, Hanhoff T, Goertler M et al. Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J. Neurol. 252(6), 718-724 (2005).
22. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D- aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem. 49(10), 1752-1762 (2003).
23. Kanner AA, Marchi N, Fazio V et al. Serum S100β: a noninvasive marker of blood - brain barrier function and brain lesions. Cancer 97(11), 2806-2813 (2003).
24. Stroick M, Fatar M, Ragoschke-Schumm A, Fassbender K, Bertsch T, Hennerici MG. Protein S-100B - a prognostic marker for cerebral damage. Curr. Med. Chem. 13(25), 3053-3060 (2006).
25. Fazio V, Bhudia SK, Marchi N, Aumayr B, Janigro D. Peripheral detection of S100β during cardiothoracic surgery: what are we really measuring? Ann. Thorac. Surg. 78(1), 46-52 (2004).
26. Foerch C, Wunderlich MT, Dvorak F et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 38(9), 2491-2495 (2007).
27. Delgado P, Alvarez Sabin J, Santamarina E et al. Plasma S100B level after acute spontaneous intracerebral hemorrhage. Stroke 37(11), 2837-2839 (2006).
28. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch. Neurol. 62(7), 1130-1134 (2005).
29. Wunderlich MT, Wallesch CW, Goertler M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J. Neurol. Sci. 227(1), 49-53 (2004).
30. Foerch C, Otto B, Singer OC et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 35(9), 2160-2164 (2004).
31. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 28(10), 1956-1960 (1997).
32. Foerch C, du Mesnil de Rochemont R, Singer O et al. S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion. J. Neurol. Neurosurg. Psychiatry 74(3), 322-325 (2003).
33. Foerch C, Curdt I, Yan B et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J. Neurol. Neurosurg. Psychiatry 77(2), 181-184 (2006).
34. Dvorak F, Haberer I, Sitzer M, Foerch C. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc. Dis. 27(1), 37-41 (2009).
35. Tombul T, Atbas C, Anlar O. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J. Clin. Neurosci. 12(4), 429-434 (2005).
36. Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 37(7), 1798-1804 (2006).
37. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke 37(4), 1113-1115 (2006).
38. Haapaniemi E, Tatlisumak T. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol. Scand. 119(3), 141-150 (2009).
39. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis. 27(3), 247-253 (2009).
40. Kang DW, Yoo SH, Chun S et al. Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke. Stroke 40(5), 1653-1658 (2009).
41. Delgado P, Alvarez-Sabin J, Abilleira S et al. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology 67(1), 94-98 (2006).
42. Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients?: why, how, and when. Stroke 40(5), 1549-1552 (2009).
43. del Zoppo GJ, Levy DE, Wasiewski WW et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 40(5), 1687-1691 (2009).
44. Turaj W, Slowik A, Dziedzic T et al. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J. Neurol. Sci. 246(1-2), 13-19 (2006).
45. Danesh J, Lewington S, Thompson SG et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294(14), 1799-1809 (2005).
46. Woodward M, Lowe GD, Campbell DJ et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 36(10), 2143-2147 (2005).
47. Castellanos M, Leira R, Serena J et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35(7), 1671-1676 (2004).
48. Bongers TN, de Maat MP, van Goor ML et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37(11), 2672-2677 (2006).
49. Sato M, Suzuki A, Nagata K, Uchiyama S. Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J. Stroke Cerebrovasc. Dis. 15(1), 1-7 (2006).
50. McGirt MJ, Lynch JR, Blessing R, Warner DS, Friedman AH, Laskowitz DT. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 51(5), 1128-1134; discussion 1134-1125 (2002).
51. McColl BW, Allan SM, Rothwell NJ. Systemic infection, inflammation and acute ischemic stroke. Neuroscience 158(3), 1049-1061 (2009).
52. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 40(5), e380-e389 (2009). •• Excellent systematic review of stroke prognostic biomarkers describing the current limitations and providing recommendations for future clinical research.
53. Cherubini A, Ruggiero C, Polidori MC, Mecocci P. Potential markers of oxidative stress in stroke. Free Radic. Biol. Med. 39(7), 841-852 (2005).
54. Chamorro A, Hallenbeck J. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 37(2), 291-293 (2006).
55. Di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36(6), 1316-1329 (2005).
56. Blann AD, Ridker PM, Lip GY. Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology? Stroke 33(9), 2141-2143 (2002).
57. Pola R. Inflammatory markers for ischaemic stroke. Thromb. Haemost. 101(5), 800-801 (2009).
58. Hashimoto H, Kitagawa K, Hougaku H et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 104(1), 63-67 (2001).
59. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke 30(5), 981-985 (1999).
60. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 33(10), 2459-2464 (2002).
61. Schwartz RS, Bayes-Genis A, Lesser JR, Sangiorgi M, Henry TD, Conover CA. Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers. J. Interv. Cardiol. 16(3), 231-242 (2003).
62. Montaner J, Molina CA, Monasterio J et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107(4), 598-603 (2003).
63. Castellanos M, Leira R, Serena J et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34(1), 40-46 (2003).
64. Tan KT, Blann AD. To stroke or not to stroke: is ICAM-1 or CRP the answer? Neurology 60(12), 1884-1885 (2003).
65. Mocco J, Choudhri TF, Mack WJ et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery 48(4), 718-721 (2001).
66. Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J. Neurol. Neurosurg. Psychiatry 74(3), 312-316 (2003).
67. Saito K, Suyama K, Nishida K, Sei Y, Basile AS. Early increases in TNF-α, IL-6 and IL-1 b levels following transient cerebral ischemia in gerbil brain. Neurosci. Lett. 206(2-3), 149-152 (1996).
68. Fassbender K, Rossol S, Kammer T et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J. Neurol. Sci. 122(2), 135-139 (1994).
69. Tarkowski E, Rosengren L, Blomstrand C et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 26(8), 1393-1398 (1995).
70. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, Hori M. Relation between interleukin-6 level and subclinical intracranial large-artery atherosclerosis. Atherosclerosis 197(1), 326-332 (2008).
71. Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb. Haemost. 101(5), 929-937 (2009).
72. Allard L, Burkhard PR, Lescuyer P et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin. Chem. 51(11), 2043-2051 (2005).
73. Efstathiou SP, Tsioulos DI, Tsiakou AG, Gratsias YE, Pefanis AV, Mountokalakis TD. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 36(9), 1915-1919 (2005).
74. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr. Opin. Lipidol. 20(5), 363-369 (2009).
75. Cano CP, Bermudez VP, Atencio HE et al. Increased serum malondialdehyde and decreased nitric oxide within 24 hours of thrombotic stroke onset. Am. J. Ther. 10(6), 473-476 (2003).
76. Ozkul A, Akyol A, Yenisey C, Arpaci E, Kiylioglu N, Tataroglu C. Oxidative stress in acute ischemic stroke. J. Clin. Neurosci. 14(11), 1062-1066 (2007).
77. Pikula A, Boger RH, Beiser AS et al. Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 40(9), 2959-2964 (2009).
78. Wanby P, Teerlink T, Brudin L et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 185(2), 271-277 (2006).
79. Makikallio AM, Makikallio TH, Korpelainen JT et al. Natriuretic peptides and mortality after stroke. Stroke 36(5), 1016-1020 (2005).
80. Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 350(7), 655-663 (2004).
81. Sviri GE, Shik V, Raz B, Soustiel JF. Role of brain natriuretic peptide in cerebral vasospasm. Acta Neurochir. (Wien.) 145(10), 851-860; discussion 860 (2003).
82. Cucchiara BL, Messe SR, Sansing L et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 40(7), 2332-2336 (2009).
83. Gorelick PB. Lipoprotein-associated phospholipase A2 and risk of stroke. Am. J. Cardiol. 101(12A), 34F-40F (2008).
84. Ovbiagele B, Starkman S, Teal P et al. Serum calcium as prognosticator in ischemic stroke. Stroke 39(8), 2231-2236 (2008).
85. Na N, Ouyang J, Taes YE, Delanghe JR. Serum free hemoglobin concentrations in healthy individuals are related to haptoglobin type. Clin. Chem. 51(9), 1754-1755 (2005).
86. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 293(13), 1653-1662 (2005).
87. Huang P, Lo LH, Chen YC, Lin RT, Shiea J, Liu CK. Serum free hemoglobin as a novel potential biomarker for acute ischemic stroke. J. Neurol. 256(4), 625-631 (2009).
88. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke 35(1), 57-63 (2004).
89. Laskowitz DT, Blessing R, Floyd J, White WD, Lynch JR. Panel of biomarkers predicts stroke. Ann. NY Acad. Sci. 1053, 30 (2005).
90. Bossuyt PM, Reitsma JB, Bruns DE et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin. Chem. 49(1), 1-6 (2003).
91. Vanni S, Polidori G, Pepe G et al. Use of biomarkers in triage of patients with suspected stroke. J. Emerg. Med. (2009) (Epub ahead of print).
92. Sibon I, Rouanet F, Meissner W, Orgogozo JM. Use of the Triage Stroke Panel in a neurologic emergency service. Am. J. Emerg. Med. 27(5), 558-562 (2009). • Good study that compares a triage stroke panel performance to a triage nurse assessment of stroke showing that the biomarker panel increased the specificity in diagnosing stroke mimics.
93. Allard L, Lescuyer P, Burgess J et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 4(8), 2242-2251 (2004).
94. Montaner J, Perea-Gainza M, Delgado P et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 39(8), 2280-2287 (2008).
95. Tuttolomondo A, Di Sciacca R, Di Raimondo D et al. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: Relationship with TOAST subtype, outcome and infarct site. J. Neuroimmunol. 215(1-2), 84-89 (2009).
96. Xu H, Tang Y, Liu DZ et al. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J. Cereb. Blood Flow Metab. 28(7), 1320-1328 (2008).
97. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke 35(6), 1421-1425 (2004).
98. Serena J, Blanco M, Castellanos M et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 36(9), 1921-1926 (2005).
99. Counsell C, Dennis M, McDowall M. Predicting functional outcome in acute stroke: comparison of a simple six variable model with other predictive systems and informal clinical prediction. J. Neurol. Neurosurg. Psychiatry 75(3), 401-405 (2004).
100. Castillo J, Alvarez-Sabín J, Martínez-Vila E, Montaner J, Sobrino T, Vivancos J; MITICO Study Investigators. Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study. J. Neurol. 256(2), 217-224 (2009)
101. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 273(18), 1421-1428 (1995).
102. Golledge J, Siew DA. Identifying the carotid 'high risk' plaque: is it still a riddle wrapped up in an enigma? Eur. J. Vasc. Endovasc. Surg. 35(1), 2-8 (2008).
103. Mannheim D, Herrmann J, Versari D et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 39(5), 1448-1455 (2008).
104. Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 114(17), 1847-1854 (2006).
105. Rost NS, Wolf PA, Kase CS et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32(11), 2575-2579 (2001).
106. van Dijk EJ, Prins ND, Vermeer SE et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 112(6), 900-905 (2005).
107. Hacke W, Warach S. Diffusion-weighted MRI as an evolving standard of care in acute stroke. Neurology 54(8), 1548-1549 (2000).
108. Pettigrew LC, Kasner SE, Gorman M, Atkinson RP, Funakoshi Y, Ishibashi H. Effect of arundic acid on serum S-100β in ischemic stroke. J. Neurol. Sci. 251(1-2), 57-61 (2006).
109. Lynch JR, Wang H, McGirt MJ et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 36(9), 2024-2026 (2005).
110. Wunderlich MT, Lins H, Skalej M, Wallesch CW, Goertler M. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin. Neurol. Neurosurg. 108(6), 558-563 (2006).
111. Abraha HD, Butterworth RJ, Bath PM, Wassif WS, Garthwaite J, Sherwood RA. Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann. Clin. Biochem. 34(Pt 4), 366-370 (1997).
112. Olivot JM, Labreuche J, Aiach M, Amarenco P. Soluble thrombomodulin and brain infarction: case-control and prospective study. Stroke 35(8), 1946-1951 (2004).
113. DeGraba TJ, Siren AL, Penix L et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 29(7), 1405-1410 (1998).
114. Hill MD, Jackowski G, Bayer N, Lawrence M, Jaeschke R. Biochemical markers in acute ischemic stroke. CMAJ 162(8), 1139-1140 (2000).